The post Non-Cellular Oncology Immunotherapy with STIP–NAM Traceability, Entering a Global Acquisition Window. appeared on BitcoinEthereumNews.com. ORLANDO, Estados Unidos, September 3rd, 2025, FinanceWire OGRD Alliance announces PLPC-DB, a non-cellular oncology immunotherapy platform designed to overcome the barriers of cost, scalability, and infrastructure in cancer innovation. Unlike cell- or gene-based therapies, PLPC-DB is a lyophilized phospholipoproteic complex with validated stability for more than 18 months at room temperature, eliminating cold-chain dependency and reducing operational costs by over 60%. FOUNDATION IN REAL-WORLD EVIDENCE For more than a decade, the OncoVix program in Latin America has provided structured patient monitoring and data collection. This Real-World Evidence (RWE) backbone enabled the creation of the Structured Immunophenotypic Traceability Platform (STIP), now enhanced with a Network Access Module (NAM). STIP–NAM extends traceability to interoperable, auditable formats across jurisdictions, supporting regulators, investors, and partners without requiring sequential Phase I–III trials. SCIENTIFIC DIFFERENTIATION PLPC-DB coordinates innate and adaptive immune activation (NK, CD8⁺, CD4⁺ Th1), enhances antigen presentation, and reduces inhibitory cytokines such as IL-10 and TGF-β. Its platform is documented in five PubMed-indexed Q1 publications and eleven Tier-1 oncology congress presentations, under the scientific leadership of Dr. Ramón Gutiérrez-Sandoval M.D., oncopathologist and CSO of OGRD Alliance. “Our priority has been to structure PLPC-DB as a scalable and traceable immunotherapy asset, with a dossier that meets the expectations of global regulators and investors,” said Dr. Ramón Gutiérrez-Sandoval, Chief Scientific Officer of OGRD Alliance. “The STIP–NAM framework ensures that this platform is not only scientifically validated but also financially sound for strategic acquisition.” MARKET AND REGULATORY PROFILE The global oncology immunotherapy market exceeds USD 120B, expanding at ~10% CAGR. Current therapies often demand complex cold chains and costly infrastructure. PLPC-DB bypasses these limitations, offering a reproducible, scalable platform aligned with sustainability goals (UN Agenda 2030, Vision 2030). External validation letters from independent regulatory consultancies confirm dossier maturity, aligned with international regulatory standards (including FDA and EMA… The post Non-Cellular Oncology Immunotherapy with STIP–NAM Traceability, Entering a Global Acquisition Window. appeared on BitcoinEthereumNews.com. ORLANDO, Estados Unidos, September 3rd, 2025, FinanceWire OGRD Alliance announces PLPC-DB, a non-cellular oncology immunotherapy platform designed to overcome the barriers of cost, scalability, and infrastructure in cancer innovation. Unlike cell- or gene-based therapies, PLPC-DB is a lyophilized phospholipoproteic complex with validated stability for more than 18 months at room temperature, eliminating cold-chain dependency and reducing operational costs by over 60%. FOUNDATION IN REAL-WORLD EVIDENCE For more than a decade, the OncoVix program in Latin America has provided structured patient monitoring and data collection. This Real-World Evidence (RWE) backbone enabled the creation of the Structured Immunophenotypic Traceability Platform (STIP), now enhanced with a Network Access Module (NAM). STIP–NAM extends traceability to interoperable, auditable formats across jurisdictions, supporting regulators, investors, and partners without requiring sequential Phase I–III trials. SCIENTIFIC DIFFERENTIATION PLPC-DB coordinates innate and adaptive immune activation (NK, CD8⁺, CD4⁺ Th1), enhances antigen presentation, and reduces inhibitory cytokines such as IL-10 and TGF-β. Its platform is documented in five PubMed-indexed Q1 publications and eleven Tier-1 oncology congress presentations, under the scientific leadership of Dr. Ramón Gutiérrez-Sandoval M.D., oncopathologist and CSO of OGRD Alliance. “Our priority has been to structure PLPC-DB as a scalable and traceable immunotherapy asset, with a dossier that meets the expectations of global regulators and investors,” said Dr. Ramón Gutiérrez-Sandoval, Chief Scientific Officer of OGRD Alliance. “The STIP–NAM framework ensures that this platform is not only scientifically validated but also financially sound for strategic acquisition.” MARKET AND REGULATORY PROFILE The global oncology immunotherapy market exceeds USD 120B, expanding at ~10% CAGR. Current therapies often demand complex cold chains and costly infrastructure. PLPC-DB bypasses these limitations, offering a reproducible, scalable platform aligned with sustainability goals (UN Agenda 2030, Vision 2030). External validation letters from independent regulatory consultancies confirm dossier maturity, aligned with international regulatory standards (including FDA and EMA…

        Highlights:  The BNB price is down 2% to $1111.46, despite the trading volume spiking 26%. The BNB on-chain demand has slipped, with the open interest plummeting 3% showing a drop in demand.  The technical outlook shows a tight tug-of-war, with the bulls attempting to overcome resistance zones.   The BNB price is down 2% today, to trade at $1111.46. Despite the plunge, the daily trading volume has soared 26% showing increased market activity among traders. However, BNB Chain has seen declining network activity, with the open interest plummeting, signaling a drop in demand.  On Chain Demand on BNB Cools Off The BNB Chain is in a state of cooldown of network activity, which indicates low on-chain demand. In most instances, when a network fails to ensure large volumes or revenues, it means that there is low demand or outflows to other networks.  BNB DeFi Data: DeFiLlama According to DeFiLlama data, the volume of the Decentralized Exchanges (DEXs) is down to at least $2.12 billion in comparison to the high of $6.313 billion on October 8, which also means low on-chain liquidity.  On the other hand, Coinglass data shows that the volume of BNB has grown by 3.97% to reach $4.95 billion. However, the open interest in BNB futures has dropped by 3.36% to reach $1.74 billion. This reduction in open interest is an indication of a conservative stance by investors since the number of new positions being opened is low. This could be an indication that investors are not so sure about the short-term price outlook. BNB Derivatives Data: CoinGlass Meanwhile, the long-to-short ratio is sitting at 0.9091. This shows that the traders are undecided on BNB price’s next move, as it sits below 1.  BNB Price Moves Into Consolidation The chart displays the BNB/USD price action on a 4-hour timeframe, with the token currently hovering around $1111.46. The 50-day Simple Moving Average (SMA) is at $1113, while the 200-day SMA sits at $1129, cushioning the bulls against upside movement. The price has mostly been trending below both SMAs, indicating that the bears are having the upper hand.  The BNB trading volume is up, soaring 26%, signaling the momentum is real. On the 4-hour chart, BNB is trading within a consolidation channel. In such a case, this pattern may act as an accumulation period, giving the bulls hind wings to break above resistance zones.  BNB/USD 4-hour chart: TradingView Zooming in, the Relative Strength Index (RSI) sits at 44.15, below the 50 level. This shows weakening momentum in the BNB market, and might lead to the RSI plunging to the oversold region if the bulls don’t regain control. In the short term, the BNB price could move up to $1113 resistance and flip it into support. A close above this zone will see the bulls target $1126 resistance, giving the bulls strength to reclaim the $1230 mark.  Conversely, if the resistance zones prove too strong, a dip towards $1012 could be plausible. In such a case, this could be a prime buy zone for the risk-takers. In the long term, if the token keeps the hype alive, the bulls may reclaim the $1375 high or higher.    eToro Platform    Best Crypto Exchange   Over 90 top cryptos to trade Regulated by top-tier entities User-friendly trading app 30+ million users    9.9   Visit eToro eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment, and you should not expect to be protected if something goes wrong.